AR103254A1 - Profármacos de creatina, composiciones y métodos de uso de estos - Google Patents
Profármacos de creatina, composiciones y métodos de uso de estosInfo
- Publication number
- AR103254A1 AR103254A1 ARP150104265A ARP150104265A AR103254A1 AR 103254 A1 AR103254 A1 AR 103254A1 AR P150104265 A ARP150104265 A AR P150104265A AR P150104265 A ARP150104265 A AR P150104265A AR 103254 A1 AR103254 A1 AR 103254A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- cycloalkyl
- aryl
- heterocycloalkylalkyl
- Prior art date
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title abstract 12
- 229960003624 creatine Drugs 0.000 title abstract 6
- 239000006046 creatine Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 38
- 125000003118 aryl group Chemical group 0.000 abstract 28
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 22
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 22
- 125000001072 heteroaryl group Chemical group 0.000 abstract 20
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 20
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 20
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 18
- 229910052739 hydrogen Inorganic materials 0.000 abstract 18
- 239000001257 hydrogen Substances 0.000 abstract 18
- 150000002431 hydrogen Chemical group 0.000 abstract 15
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 10
- 150000001875 compounds Chemical class 0.000 abstract 8
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 102000004420 Creatine Kinase Human genes 0.000 abstract 2
- 108010042126 Creatine kinase Proteins 0.000 abstract 2
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 2
- 208000016361 genetic disease Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 239000012466 permeate Substances 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102100023153 Sodium- and chloride-dependent creatine transporter 1 Human genes 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 108010007169 creatine transporter Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/06—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095295P | 2014-12-22 | 2014-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103254A1 true AR103254A1 (es) | 2017-04-26 |
Family
ID=56128653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104265A AR103254A1 (es) | 2014-12-22 | 2015-12-22 | Profármacos de creatina, composiciones y métodos de uso de estos |
| ARP210101331A AR122096A2 (es) | 2014-12-22 | 2021-05-14 | Compuestos profármacos de creatina y composiciones que los comprenden |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101331A AR122096A2 (es) | 2014-12-22 | 2021-05-14 | Compuestos profármacos de creatina y composiciones que los comprenden |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9617230B2 (enExample) |
| EP (2) | EP3771709B1 (enExample) |
| JP (4) | JP6692372B2 (enExample) |
| AR (2) | AR103254A1 (enExample) |
| CA (1) | CA2971729C (enExample) |
| ES (1) | ES2832333T3 (enExample) |
| TW (3) | TWI832450B (enExample) |
| WO (1) | WO2016106284A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| US11021501B2 (en) | 2015-03-30 | 2021-06-01 | Farmington Pharma Development | Creatine phosphate analog prodrugs, compositions and methods of use thereof |
| WO2019109067A2 (en) * | 2017-12-01 | 2019-06-06 | Ultragenyx Pharmaceutical Inc. | Creatine prodrugs, compositions and methods of use thereof |
| CN110746325A (zh) * | 2018-07-24 | 2020-02-04 | 上海和辉光电有限公司 | 一种基于胍骨架的n型掺杂化合物及其应用 |
| CN114419050B (zh) * | 2022-03-31 | 2022-06-21 | 武汉大学 | 胃黏膜可视化程度量化方法、装置、终端及可读存储介质 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| ATE131851T1 (de) | 1991-07-19 | 1996-01-15 | Uniroyal Chem Co Inc | Zusammensetzungen zur verwendung von filmen auf saatgut |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
| EP2327404A1 (en) | 1994-11-08 | 2011-06-01 | Avicena Group, Inc. | Use of creatine or creatine analogs for the treatment of diseases of the nervous system |
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| JPH11513671A (ja) | 1995-10-11 | 1999-11-24 | アヴィセナ グループ，インク． | 糖代謝異常の治療のためのクレアチン類似体の利用 |
| US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| US6008252A (en) * | 1996-07-26 | 1999-12-28 | Beale; Paxton K. | Method for increasing muscle mass in a mammal |
| US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| EP1003476B1 (en) | 1997-08-11 | 2004-12-22 | ALZA Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| US20030008007A1 (en) | 2001-04-23 | 2003-01-09 | Jose Gutierrez-Rocca | Release pharmaceutical construct for gastric retention |
| US20030013767A1 (en) | 2001-07-13 | 2003-01-16 | Samuel Bessman | Method of treating weight loss using creatine |
| US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| EP1461019A2 (en) | 2001-12-15 | 2004-09-29 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
| NZ533784A (en) | 2002-01-03 | 2006-08-31 | Smithkline Beecham Corp | Novel pharmaceutical dosage forms and method for producing same |
| DE10221344A1 (de) | 2002-05-14 | 2003-12-04 | Hannover Med Hochschule | Transgene Ratte und ihre Verwendung im Tiermodell für die humane Chorea Huntington Erkrankung sowie Nukleinsäurekonstrukte, Vektoren und Zellen zu ihrer Erzeugung |
| EP1556413A4 (en) | 2002-05-17 | 2009-07-08 | Esperion Therapeutics Inc | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC REPERFUSION |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| US20060013876A1 (en) | 2002-06-26 | 2006-01-19 | Lohray Braj B | Novel floating dosage form |
| US20040120983A1 (en) * | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
| WO2005108370A1 (ja) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| US20070012105A1 (en) | 2005-07-13 | 2007-01-18 | Barnes-Jewish Hospital | Method and apparatus for resistive characteristic assessment |
| US20070032750A1 (en) | 2005-07-15 | 2007-02-08 | Jeffrey Oster | Muscle strength assessment system |
| WO2007146085A2 (en) | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Creatine phosphate prodrugs, compositions and uses thereof |
| US20070281995A1 (en) * | 2006-06-06 | 2007-12-06 | Xenoport, Inc. | Creatine analog prodrugs, compositions and uses thereof |
| US7683043B2 (en) | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| WO2008101310A1 (en) * | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| US7319157B1 (en) | 2007-02-20 | 2008-01-15 | Multi Formulations Ltd. | Creatine-fatty acids |
| US8426395B2 (en) | 2008-05-30 | 2013-04-23 | Northern Northern Innovations Holding Corp | Preparations containing creatine and imino sugars |
| WO2010005692A2 (en) | 2008-06-16 | 2010-01-14 | E. I. Du Pont De Nemours And Company | Insecticidal cyclic carbonyl amidines |
| AU2012312654B2 (en) | 2011-09-19 | 2017-04-13 | Gencia Corporation | Modified creatine compounds |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| EP2692719B1 (en) * | 2012-07-30 | 2016-06-08 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof |
| ITTO20121098A1 (it) * | 2012-12-18 | 2014-06-19 | Univ Degli Studi Genova | Procedimento per sintetizzare derivati della creatina |
| WO2015069699A1 (en) * | 2013-11-05 | 2015-05-14 | Ultragenyx Pharmaceutical Inc. | Creatine analogs and the use thereof |
| ITTO20131070A1 (it) * | 2013-12-24 | 2015-06-25 | Univ Degli Studi Genova | Applicazione terapeutica di un derivato di creatina |
| US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
| WO2016110822A1 (en) * | 2015-01-09 | 2016-07-14 | Universita' Degli Studi Di Genova | Carboxylic biacyl creatine derivative, uses and method of synthesis thereof |
| US11021501B2 (en) | 2015-03-30 | 2021-06-01 | Farmington Pharma Development | Creatine phosphate analog prodrugs, compositions and methods of use thereof |
-
2015
- 2015-12-21 US US14/975,950 patent/US9617230B2/en active Active
- 2015-12-22 JP JP2017552008A patent/JP6692372B2/ja active Active
- 2015-12-22 TW TW111136599A patent/TWI832450B/zh active
- 2015-12-22 ES ES15874283T patent/ES2832333T3/es active Active
- 2015-12-22 EP EP20184803.3A patent/EP3771709B1/en active Active
- 2015-12-22 WO PCT/US2015/067283 patent/WO2016106284A2/en not_active Ceased
- 2015-12-22 CA CA2971729A patent/CA2971729C/en active Active
- 2015-12-22 AR ARP150104265A patent/AR103254A1/es active IP Right Grant
- 2015-12-22 TW TW109123072A patent/TWI779312B/zh active
- 2015-12-22 TW TW104143162A patent/TWI700270B/zh active
- 2015-12-22 EP EP15874283.3A patent/EP3237391B1/en active Active
-
2017
- 2017-04-07 US US15/481,568 patent/US10344007B2/en active Active
-
2019
- 2019-05-22 US US16/419,596 patent/US11407722B2/en active Active
-
2020
- 2020-04-14 JP JP2020072408A patent/JP7037597B2/ja active Active
-
2021
- 2021-05-14 AR ARP210101331A patent/AR122096A2/es unknown
-
2022
- 2022-03-04 JP JP2022033882A patent/JP7676338B2/ja active Active
-
2025
- 2025-04-30 JP JP2025075259A patent/JP2025118733A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016106284A2 (en) | 2016-06-30 |
| US10344007B2 (en) | 2019-07-09 |
| US20160176829A1 (en) | 2016-06-23 |
| CA2971729C (en) | 2024-02-20 |
| TW202041504A (zh) | 2020-11-16 |
| US9617230B2 (en) | 2017-04-11 |
| CA2971729A1 (en) | 2016-06-30 |
| WO2016106284A3 (en) | 2016-10-13 |
| US20170342039A1 (en) | 2017-11-30 |
| JP2018502911A (ja) | 2018-02-01 |
| TWI779312B (zh) | 2022-10-01 |
| EP3771709B1 (en) | 2024-03-20 |
| TW201629011A (zh) | 2016-08-16 |
| TW202304854A (zh) | 2023-02-01 |
| AR122096A2 (es) | 2022-08-10 |
| TWI832450B (zh) | 2024-02-11 |
| JP2022078213A (ja) | 2022-05-24 |
| US11407722B2 (en) | 2022-08-09 |
| JP2025118733A (ja) | 2025-08-13 |
| JP7676338B2 (ja) | 2025-05-14 |
| JP2020128379A (ja) | 2020-08-27 |
| EP3771709A1 (en) | 2021-02-03 |
| EP3237391B1 (en) | 2020-09-02 |
| EP3237391A2 (en) | 2017-11-01 |
| JP6692372B2 (ja) | 2020-05-13 |
| TWI700270B (zh) | 2020-08-01 |
| ES2832333T3 (es) | 2021-06-10 |
| EP3237391A4 (en) | 2018-10-03 |
| US20190337909A1 (en) | 2019-11-07 |
| EP3771709C0 (en) | 2024-03-20 |
| JP7037597B2 (ja) | 2022-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202100027A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| AR122096A2 (es) | Compuestos profármacos de creatina y composiciones que los comprenden | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| AR109595A1 (es) | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| CO7230336A2 (es) | Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos | |
| EA201491592A1 (ru) | Соединения индолов и индазолов, активирующие ampk | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen | |
| AR094735A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4 | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| MX366820B (es) | Moduladores de gpr120 del acido biciclo[2.2.2]. | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| MX2018014164A (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico. | |
| CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
| MX384293B (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefálica | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| AR097772A1 (es) | Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediado por actividad quinurenina-3-monooxigenasa | |
| AR097157A1 (es) | COMPUESTOS DE DIÓXIDO DE AMINO TIAZINA BICÍCLICOS PUNTEADOS COMO INHIBIDORES DE b-SECRETASA Y SUS MÉTODOS DE USO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |